mRNA Vaccines; DNA Will Be Hit!

John Catanzaro
4 min readFeb 6, 2021

2021 John A. Catanzaro

Translate, please! On many occasions, while in Mexico, I put together and associate words in English; however, sometimes, the English word equivalent was not sufficient to describe the Spanish word’s full meaning.

As we continue to observe emerging problems with the increasing bad reactions to the current Pfizer and Moderna mRNA vaccines, two words can describe such reactions, random and unpredictable.

Just as saying the wrong word at the wrong time can be often embarrassing and potentially damaging because of the inadequate understanding of the spoken language, so can mRNA misdirected translation be toxic and unpredictable.

The current mRNA vaccine designs alter the inherent quality control mechanisms of the human cell and systems. Aberrant, misfolded, and mislocalized proteins are often toxic to human cells and can result in many human diseases. Vaccinated individuals experience a perplexing degree of symptoms that mimic disease, and many have died from poisonous reactions.

“Translation” is a keyword here. Several distinct mechanisms control the quality of mRNA and proteins during the translation process. mRNA quality control systems include nonsense-mediated decay (NMD), non-stop decay (NSD), and no-go decay (NGD). Failure of an intact quality system will result in random rogue reactions resulting in severe downstream consequences. All proteins of the human body are subject to these quality control mechanisms. This quality mRNA control system influences what is collectively known as the protein to protein interaction (PPI) system. A single misplaced failure can virtually affect downstream proteins responsible for controlling and maintaining human body systems.

The current mRNA vaccine design used a segment of viral-related mRNA with the hope of producing an immune response using a viral mimicry mechanism that makes random fragment protein segments with the action of eliciting an immune response. This technology is new and not fully understood.

Genetic information during transcription and translation into correctly folded active proteins localized at the proper places for their functioning is a normal process of maintaining quality control. Despite high fidelity quality control mechanisms, defective proteins can result from mutations, mistakes in transcription, stress, or other reasons. This phenomenon may explain the basis of the varied adverse severe…



John Catanzaro

John A. Catanzaro is CEO of Neo7logix, a bioscience company that designs precision and personalized treatment designs.